サンプル依頼リスト カート
  • English
  • Korean
表紙：アンジオテンシン変換酵素阻害薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1372612

アンジオテンシン変換酵素阻害薬の世界市場-2023年～2030年

Global Angiotensin-Converting Enzyme Inhibitors (ACE) Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
アンジオテンシン変換酵素阻害薬の世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

アンジオテンシン変換酵素阻害剤は、心血管疾患、腎疾患、糖尿病などの治療に使用される薬剤の一種です。アンジオテンシン変換酵素阻害剤は、他の薬剤と組み合わせて高血圧の治療に使用されます。FDAが承認した用途には、収縮期心不全の補助療法が含まれます。また、心筋感染症にも使用されます。

作用機序としては、血圧を下げるアンジオテンシン変換酵素を阻害します。高血圧の治療以外にも、これらの阻害薬はネフローゼ症候群、糸球体感染症、その他の腎臓の炎症など、いくつかの腎臓病を治療します。リシノプリルやベナゼプリルがアンジオテンシン変換酵素阻害剤の有名な例です。

市場力学：市場促進要因と市場抑制要因

心血管疾患の増加

心血管疾患は、世界中で主要な死因の一つです。世界保健機関（WHO）によると、2023年には年間推定1,700万人が、主に脳卒中や心臓発作などの心血管疾患が原因で死亡すると推定されています。不健康な食習慣や糖尿病、高血圧などの基礎疾患により、多くの人が心臓発作を起こします。

さらに、英国心臓財団によると、2023年には6億2,000万人近くが心臓病を患っているといいます。世界全体では、現在13人に1人が心臓病や循環器系疾患を患っていると推定されています。毎年、6,000万人以上が心臓病を発症しており、これは英国の人口とほぼ同じです。

2023年3月、Harvard Business School 2023によると、若年成人の間で糖尿病や高血圧とともに心血管疾患のリスクが増加していることが明らかになっています。

アンジオテンシン変換酵素阻害薬治療の副作用

アンジオテンシン変換酵素阻害薬は高血圧の治療に用いられるが、時に他の降圧薬と併用すると低血圧を引き起こします。アンジオテンシン変換酵素阻害薬を過剰に使用すると、カリウム値が上昇する高カリウム血症になります。薬物有害反応の可能性があり、まれに血管浮腫を起こすことがあるが、これは生命を脅かす事態です。心不全や腎灌流不良の患者では、アンジオテンシン変換酵素阻害薬治療により糸球体濾過率がさらに低下します。

本レポートの詳細について- サンプル請求

目次

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 心血管疾患の増加
      • YY
    • 抑制要因
      • アンジオテンシン変換酵素阻害薬による副作用
      • YY
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 心血管疾患統計
  • 規制分析
  • DMIオピニオン

第6章 COVID-19分析

第7章 薬剤タイプ別

  • ジカルボン酸塩含有薬
    • エナラプリル
    • ラミプリル
    • キナプリル
    • その他
  • ホスホン酸塩含有製剤
    • ホシノプリル
    • その他
  • スルフヒドリル含有製剤
    • アラセプリル
    • カプトプリル
    • その他
  • その他

第8章 用途別

  • 心血管疾患
  • 腎臓疾患
  • 糖尿病
  • 高血圧症
  • その他

第9章 投与経路別

  • 経口
  • 非経口
  • その他

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Camber Pharmaceuticals, Inc.
  • Pfizer Inc
  • Merck & Co., Inc
  • Biogaran
  • Lupin Pharmaceuticals, Inc.
  • Crescent Pharma Limited
  • Global Pharma Pvt Ltd
  • SCHWITZ BIOTECH
  • Steris Healthcare PVT Ltd
  • Auro Pharma Inc

第14章 付録

目次
Product Code: PH2029

Overview

ACE inhibitors are a class of medication used for treating cardiovascular diseases, renal diseases, diabetes mellitus, etc. They are used to treat hypertension in combination with other drugs. The FDA-approved uses include adjunctive therapy in systolic heart failure. It is also used for myocardial infection.

The mechanism of action involves the blockage of the angiotensin-converting enzyme that lowers the blood pressure. Besides treating hypertension, these inhibitors treat several kidney diseases like nephrotic syndrome, glomerular infections, and other kidney inflammations. Lisinopril and benazepril are famous examples of ACE inhibitors.

Market Dynamics: Drivers & Restraints

Increasing prevalence of cardiovascular diseases

Cardiovascular diseases are one of the leading causes of death around the world. According to the World Health Organisation, 2023, an estimated 17 million people die annually due to cardiovascular diseases, mainly stroke and heart attacks. It affects men and women equally due to unhealthy diet habits and underlying health ailments like diabetes, hypertension, etc, which lead to heart strokes in many individuals.

Furthermore, according to the British Heart Foundation, 2023, nearly 620 million people live with cardiac diseases. Globally, it is estimated that 1 in 13 individuals currently suffer from heart or circulatory disease. Each year, more than 60 million people develop cardiac diseases, which are almost the same as the population of the UK.

In March 2023, according to Harvard Business School 2023, the study revealed an increased risk of cardiovascular diseases along with diabetes and hypertension among young adults.

Side effects of ACE inhibitor therapy

ACE inhibitors are used to treat hypertension, but sometimes, when given with other anti-hypertensive agents, it leads to hypotension. Excessive usage of ACE inhibitors leads to hyperkalemia, where increased potassium levels are seen. Adverse drug reaction is possible, leading to angioedema, a rare but life-threatening situation. Patients with heart failure and poor renal perfusion lead to further reduction of glomerular filtration rate with ACE inhibitor therapy.

For more details on this report - Request for Sample

Segment Analysis

The global angiotensin-converting enzyme inhibitors (ACE) are segmented based on drug type, application, route of administration, distribution channel, and region.

The Dicarboxylic-containing agents segment accounted for approximately 47.1% of the market share

Dicarboxylic-containing ACE inhibitors are expected to hold the largest share of the market. ACE inhibitors are under clinical trial for treating diseases like cardiovascular, lung, renal, etc. A combination therapy containing ACE inhibitors is given to patients suffering from cardiac ailments and other diseases.

In September 2023, Pharmascience Inc. launched PERINDOPRIL-INDAPAMIDE, a combination of an angiotensin-converting enzyme (ACE) inhibitor and diuretic to lower blood pressure in hypertensive patients of all ages.

The Centre for Chronic Disease Control, India, along with Imperial College London, All India Institute of Medical Sciences, New Delhi, is conducting phase 4 clinical trials to compare the efficacy of three single-pill combinations of two anti-hypertensive agents, Amlodipine and Perindopril. The study start date is August 30, 2022. The estimated completion date is December 31, 2023.

Geographical Analysis

North America accounted for approximately 39.6% of the market share in 2022

North America is expected to hold the largest market share due to the prevalence of diabetes mellitus in the US and Canada. ACE inhibitors are used to treat diabetes mellitus, hypertension, etc., due to their efficacy in blocking the angiotensin enzyme in the body.

For instance, according to the Pan American Health Organization, 62 million people live with diabetes in the Americas, which is expected to be much higher given that around 40% of those without any symptoms. Diabetes is America's sixth leading cause of mortality and was responsible for over 284,000 deaths in 2019. The prevalence of type 2 diabetes is increasing drastically due to unhealthy food habits and sedentary lifestyles in America.

According to the USC Schaeffer Center for Health Policy & Economics, in 2023, about 70% of Americans will have high blood pressure in their lifetimes. Only 1 in 4 patients with hypertension were in control, and others are asymptomatic.

COVID-19 Impact Analysis:

COVID-19 moderately impacted the angiotensin enzyme inhibitor market. Disruption in the supply chain was observed during the pandemic. People who contracted COVID-19 mainly have underlying co-morbidities like diabetes, hypertension, and heart ailments. As there is no termination in the drug intake by people suffering from heart ailments, there is not much impact observed on ACE inhibitors market. The implementation of lockdowns worldwide made testing and diagnosing cardiovascular diseases difficult because there is a high fear of contracting the disease.

Competitive Landscape

The major global players in the angiotensin-converting enzyme inhibitors (ACE) market include: Camber Pharmaceuticals, Inc., Pfizer Inc, Merck & Co., Inc, Biogaran, Lupin Pharmaceuticals, Inc., Crescent Pharma Limited, Global Pharma Pvt Ltd, SCHWITZ BIOTECH, Steris Healthcare PVT Ltd, Auro Pharma Inc among others.

Key Developments

  • In February 2021, Novartis received US Food and Drug Administration approval for Entresto for the treatment of chronic heart failure.
  • In January 2021, Merck & Co, Inc., received US Food and Drug Administration approval for VERQUVO for the treatment of chronic heart failure specifically approved for patients following a hospitalization for heart failure. It is jointly developed with Bayer AG.

Why Purchase the Report?

  • To visualize the global angiotensin-converting enzyme inhibitors market segmentation based on drug type, application, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of angiotensin-converting enzyme inhibitors market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global angiotensin-converting enzyme inhibitors (ACE) market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Increasing prevalence of cardiovascular diseases
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects of ACE inhibitor therapy
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Cardiovascular disease statistics
  • 5.5. Regulatory Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Dicarboxylate-containing Agents *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 7.2.2.1. Enalapril
      • 7.2.2.2. Ramipril
      • 7.2.2.3. Quinapril
      • 7.2.2.4. Others
  • 7.3. Phosphonate-containing Agents
    • 7.3.1. Fosinopril
    • 7.3.2. Others
  • 7.4. Sulfhydryl-containing Agents
    • 7.4.1. Alacepril
    • 7.4.2. Captopril
    • 7.4.3. Others
  • 7.5. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiovascular Diseases*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Renal Diseases
  • 8.4. Diabetes
  • 8.5. Hypertension
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Camber Pharmaceuticals, Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Pfizer Inc
  • 13.3. Merck & Co., Inc
  • 13.4. Biogaran
  • 13.5. Lupin Pharmaceuticals, Inc.
  • 13.6. Crescent Pharma Limited
  • 13.7. Global Pharma Pvt Ltd
  • 13.8. SCHWITZ BIOTECH
  • 13.9. Steris Healthcare PVT Ltd
  • 13.10. Auro Pharma Inc

LIST NOT EXHAUSTIVE.

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us